[18F]FDG	Fluorodeoxyglucose
4E-BP1	Eukaryotic translation initiation factor 4E-binding protein 1
ABC	Activated B-cell
AE	Adverse event
ALT	Alanine aminotransferase
AR	Androgen receptor
AR-V7	Androgen receptor variant 7
AST	Aspartate aminotransferase
AUC	Area under the curve
BCL	B-cell lymphoma
BICR-PFS	Blinded independent central review of progression-free survival
BID	Twice daily
BLRM	Bayesian logistic regression model
BRCA1	Breast cancer A1
BAP1	BRCA1-associated protein-1
BRD4	Bromodomain-containing protein 4
BTC	Biliary tract cancer
BTK	Bruton’s tyrosine kinase
CARD11	Caspase recruitment domain family member 11
CBR	Clinical benefit rate
CCL-3	Chemokine ligand 3
CCL-4	Chemokine ligand 4
CDK4/6	Cyclin-dependent kinase 4/6
CI	Confidence interval
CLL	Chronic lymphocytic leukemia
Cmax	Maximum concentration drug achieves in a specified compartment
CNS	Central nervous system
CR	Complete response
CRPC	Castration-resistant prostate cancer
mCRPC	Metastatic castration-resistant prostate cancer
CTCL	Cutaneous T-cell lymphoma
CYP450	Cytochromes P450
CXCL	C-X-C motif ligand
DCR	Disease control rate
DL	Dose level
DLBCL	Diffuse large B-cell lymphoma
DLT	Dose-limiting toxicities
DoR	Duration of response
EGFR	Epidermal growth factor receptor
ER	Estrogen receptor
ERK	Extracellular-signal regulated kinase
ESR1	Estrogen receptor 1
ESCO1	Establishment of sister chromatid cohesion N-acetyltransferase 1
FANCE	Fanconi anemia, complementation group E
FGFR2	Fibroblast growth factor receptor 2
FL	Follicular lymphoma
FEP	Full evaluable population
FOXO3	Forkhead box O3
GATA3	GATA-binding protein 3
GBC	Germinal center B-cell
GSK3ß	Glycogen synthase kinase 3 beta
GCIG	Gynecological cancer intergroup
HDAC	Histone deacetylases
HER2	Human epidermal growth factor receptor 2
HIF-1α	Hypoxia-inducible factor-1α
HNSCC	Head and neck squamous cell carcinoma
HPV	Human papilloma virus
HR	Hormone receptor
HL	Hodgkin’s lymphoma
IC50	Half-maximal inhibitory concentration
iwCLL	International workshop on chronic lymphocytic leukemia
IHC	Immunohostochemistry
IQR	Interquartile range
IMRT	Intensity-modulated radiotherapy
IV	Intravenous
KRAS	Kirsten rat sarcoma
LAR	Luminal androgen receptor
LASCCHN	Locally advanced squamous cell cancer of the head and neck
LDH	Lactate dehydrogenase
LKB1	Liver kinase B1
LL	Lymphocytic leukemia
mAb	Monoclonal antibody
MAPK	Mitogen-activated protein kinase
MBC	Metastatic breast cancer
MCL	Mantle cell lymphoma
MCL1	Induced myeloid leukemia cell differentiation protein
MDM2	Mouse double minute 2 homolog
MTD	Maximum tolerated dose
MR	Major response
mRNA	Messenger ribonucleic acid
MRR	Major response rate
mTOR	Mechanistic target of rapamycin
MZL	Marginal zone lymphoma
NCI	National Cancer Institute
NK	Natural killer
MYD	Myeloid differentiation protein
NCRNPD	Neither complete response nor progressive disease
N.E.	Not estimated
NFKBIA	NF-kappaB inhibitor alpha
NGS	Next-generation sequencing
iNHL	Indolent non-Hodgkin lymphoma
NK	Natural Killer cells
N.R.	Not reachable
MRI	Magnetic resonance imaging
NSCLC	Non-small-cell lung cancer
OR	Overall response
ORR	Overall response rate
OS	Overall survival
PAM 50	Prediction analysis of microarray 50
PCNSL	Primary central nervous system lymphoma
PAP	Primary analysis population
PCWG2	Prostate Cancer Clinical Trials Working Group
PD	Progressive disease
PDGFRA	Platelet-derived growth factor receptor alpha
PET	Positron emission tomography
PI3K	Phosphoinositide 3-kinase
PIK3CA	Phosphatidylinosi-tol-4,5- bisphosphate 3-kinase catalytic subunit alpha
PPS	Per protocol sets
PFS	Progression-free survival
PO	Oral
PgR	Progesterone receptor
PJP	Pneumocystis jirovecii pneumonia
PK	Pharmacokinetics
PR	Partial response
PRP	Platelet rich plasma
PRAS40	Proline rich AKT substrate of 40 kDa
PRES	Posterior reversible encephalopathy syndrome
pS6	Ribosomal protein S6
PSA	Prostate-specific antigen
PTCL	Peripheral T cell lymphoma
PTEN	Phosphatase and tensin homolog
QD	Once daily
RDE	Recommended dose on expansion
RECIST	Response evaluation criteria in solid tumors
RB	Retinoblastoma
RP2D	Recommended phase 2 dose
RPPA	Reverse phase protein array
RPS32	Ribosomal protein small subunit 32
R/R	Relapsed refractory
SCNSL	Secondary central nervous system lymphoma
SD	Stable disease
SETD2	SET domaincontaining 2, histone lysine methyltransferase
SGLT2	Sodium-glucose cotransporter-2
SLL	Small lymphocytic lymphoma
T1/2	Half-life
TEAEs	Treatment emergent adverse events
Tmax	Time to reach maximum concentration
TNBC	Triple-negative breast cancer
TNFAIP3	TNF alpha induced protein 3
TP53	Tumor protein 53
TTF	Time-to-treatment failure
TTR	Time to response
VEGF	Vascular endothelial growth factor
VGPR	Very good partial response
WT	Wild type